Clinical Trial

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial

Study acronym: MEGALiT
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, open-label, non-randomized combined basket- and umbrella trial divided in two parts; a limited feasibility-oriented part 1 including 154 patients and 3 treatment cohorts and part 2 that will include an expanded cohort of patients and treatment cohorts. The overall aims of the study are to test the feasibility, safety and efficacy of comprehensive genomic profiling on fresh tumor biopsies as a basis for treatment decision making and to compare two different sequencing, bioinformatics and decision-making platforms (part 1). Also to evaluate the efficacy and safety of off-label treatment with cancer drugs in patients selected based on genomic biomarker matching.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-12-02; most recent amendment 2024-08-20.
Status change: Recruiting → Active, Not Recruiting 2024-08-20
Status change: Not Yet Recruiting → Recruiting 2020-10-26
Trial Details
NCT Number NCT04185831
Lead Sponsor Uppsala University Hospital
Conditions Solid Tumor
Enrollment 167 participants
Start Date 2020-10-20
Primary Completion 2024-01-31 (estimated)
Study Completion 2024-10 (estimated)
Updated on ClinicalTrials.gov 2024-08-22